Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms FCR
- 04 Oct 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.
- 04 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
- 11 Apr 2019 Planned End Date changed from 1 Aug 2018 to 1 Oct 2019.